Skip to main content

Fluicell

HardwareGothenburg, SwedenFounded 2012· One of 1636 Hardware companies tracked by AMPulse

Develops high-resolution single-cell bioprinters (Biopixlar®) for tissue engineering and drug development, enabling precise 3D tissue fabrication without bioink.

CEO / Founder
Carolina Trkulja
Team Size
11-50
Stage
Active
Total Funding
$600K
Latest Round
Grant
Key Investors
Avanza Pension, Viola Vitalis AB, Nordnet Pensionsförsäkrning, Niklas Frisk, Thomas Claes Alarik Alander, Gökhan Ziyanak, Andreas Holmström, Krister Hultberg, Magnus Folkesson, Björn Hörlin

Technology & Products

Key Products

Biopixlar (modular research platform for single cell arrays, organoids, and complex tissues), BioPen, Dynaflow Resolve, Biopixlar AER (compact 3D bioprinter).

Technical position · AMPulse analysis

Proprietary open-volume microfluidics technology achieves >95% cell viability and single-cell precision, protected by 5 patent families; first commercial microfluidics-based high-resolution bioprinter without bioink.

Differentiation

Value Proposition

Reduces tissue model development time from months to days with single-cell precision (>95% viability), enabling faster drug screening and personalized medicine at lower cost per assay.

How They Differentiate

3x higher cell viability (>95% vs ~80% for conventional bioprinters) and single-cell resolution without bioink, unlike competitors relying on bioink-based extrusion; Biopixlar AER is 50% more compact than standard bioprinters for lab integration.

Market & Competition

Target Customers

Pharmaceutical companies, academic research labs, biotech firms

Industry Verticals

Pharmaceuticals; Biotechnology; Academic Research; Regenerative Medicine

Competitors

Organovo, Advanced Solutions, Allevi, CELLINK

Growth & Milestones

Growth Metrics

Installed base of Biopixlar systems at 10+ research institutions globally; 2023 revenue SEK 8.9 million (approximately $850,000 USD); 2022 revenue SEK 6.8 million (approximately $650,000 USD) representing 31% year-over-year growth

Major Milestones

Launched Biopixlar® AER in Q1 2022; Signed first beta testing agreement with Cellectricon AB; Developed Nexocyte™ platform for tissue-based therapeutics

Notable Customers

Dr. Luiz Bertassoni, Director Knight Cancer Precision Biofabrication Hub; Dr. Dani Cai, National Institute of Health; Prof. Megan Rizzo, University of Maryland Medical Center; Dr. Veronica Jove, Rockefeller University; Dr. Timm Danker, NMI TT

https://fluicell.com

AM patents

AM-relevant patents linked to this company.

Patents
6
Granted
1
Families
6

Leading domains: application (6), process (6)

Filings by year: 2020: 2 · 2019: 2 · 2017: 2

  1. METHODS AND SYSTEMS FOR GENERATING THREE-DIMENSIONAL BIOLOGICAL STRUCTURES20220389373 · US
  2. Cell printing utilizing recirculating fluid flows12012578 · US
  3. METHODS AND SYSTEMS FOR GENERATING THREE-DIMENSIONAL BIOLOGICAL STRUCTURES04048331 · EP
  4. METHODS ADN SYSTEMS UTILIZING RECIRCULATING FLUID FLOWS2019021061 · WO
  5. METHODS AND SYSTEMS FOR GENERATING THREE-DIMENSIONAL BIOLOGICAL STRUCTURES2021079192 · WO

Funding rounds

  • Grant$600,0002021-03-01Source
  • Post-IPO Equity$451,4602020-10-16Source: Crunchbase